DIHEXA 5 mg

DIHEXA 5 mg is a research peptide studied for its effects on synaptic connectivity and cognition in preclinical models. It is an angiotensin IV analog that potentiates HGF/c-Met signaling . It has never been approved for human use and is sold strictly for laboratory research purposes.

No established human dosage exists. In animal studies, 2 mg/kg/day orally was used . In non-medical community contexts, oral doses of 5-20 mg daily are referenced . DIHEXA has a half-life of approximately 12.7 days, which means it accumulates with daily dosing .

DIHEXA has no relationship to the hypothalamic-pituitary-gonadal axis and is not part of any post-cycle therapy protocol. Its research focus has been on synaptic connectivity and cognition, not hormonal recovery. PCT compounds such as Clomid and Nolvadex address entirely different biological systems.

DIHEXA is an angiotensin IV analog that binds to hepatocyte growth factor (HGF) with high affinity and potentiates its activity at the c-Met receptor . This activation of the HGF/c-Met pathway has been associated with hippocampal spinogenesis and synaptogenesis in preclinical models . In a 2021 study, DIHEXA restored cognitive function in APP/PS1 Alzheimer's model mice .

No human data exists on the time course of DIHEXA effects. In animal studies, cognitive improvements were observed over treatment periods of weeks to months . DIHEXA has a half-life of approximately 12.7 days, which means steady-state levels accumulate slowly over several weeks of daily dosing .

There is no single cognitive peptide that is universally best, and DIHEXA's evidence base is particularly weak. A key 2014 study was retracted, and no human trials have been conducted . Other research peptides like Semax have different mechanisms and evidence profiles. The appropriate choice depends on research goals and a careful assessment of available evidence.

DIHEXA and Semax have different mechanisms. DIHEXA is an angiotensin IV analog that potentiates HGF/c-Met signaling, while Semax is a synthetic ACTH fragment that upregulates BDNF and modulates other neurotrophic pathways. Both are research peptides with different evidence bases and proposed applications.

DIHEXA and Cerebrolysin are fundamentally different. DIHEXA is a small synthetic angiotensin IV analog that potentiates HGF/c-Met signaling. Cerebrolysin is a mixture of neurotrophic peptides and amino acids derived from pig brain. They have different compositions, mechanisms, and evidence bases.

No human dosing standards exist for DIHEXA. The 5 mg vial strength is a research quantity. In non-medical community contexts, 5-20 mg daily is referenced, so a 5 mg vial provides 1-4 doses depending on the protocol. DIHEXA is dosed in milligrams, not micrograms, which is unusual for peptides .

DIHEXA 5 mg is labeled at 5 mg of DIHEXA per vial. It is supplied as a lyophilized powder in a 2 mL vial, requiring reconstitution before laboratory use.

This product page does not include a published laboratory report for the current batch. Independent testing of commercial DIHEXA samples has found significant purity issues, with 9 of 12 samples below 95% purity . For researchers requiring batch-specific testing documentation, please contact customer support.

This is not known. DIHEXA activates the HGF/c-Met pathway, which is implicated in cancer progression when overactive . The FDA has approved drugs specifically to block c-Met for cancer treatment. A compound that stimulates this pathway with no long-term safety data raises a legitimate theoretical concern that has not been studied . No human or animal long-term safety data exists to answer this question .